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ZBTB4 is a transcriptional repressor and examination of publically-available microarray data sets demonstrated an
inverse relationship in the prognostic value and expression of ZBTB4 and the histone methyltransferase EZH2 in
tumors from breast cancer patients. The possibility of functional interactions between EZH2 and ZBTB4 was
investigated in breast cancer cells and the results showed that EZH2 is directly suppressed by ZBTB4 which in turn
is regulated (suppressed) by miR-106b and other paralogues from the miR-17-92, miR-106b-25 and miR-106a-363
clusters that are highly expressed in breast and other tumors. ZBTB4 also acts a suppressor of specificity protein
(Sp) transcription factors Sp1, Sp3 and Sp4, and RNA interference studies show that Sp proteins are required for
EZH2 expression. The prediction analysis results from breast cancer patient array data sets confirm an association
of Sp1-dependent EZH2 gene signature with decreased survival of breast cancer patients. Disruption of oncogenic
miR-ZBTB4 signaling axis by anticancer agent such as betulinic acid that induce down-regulation of Sp proteins in
breast cancer cells resulted in inhibition of tumor growth and colonization of breast cancer cells in a mouse model.
Thus, EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs and
ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and
possibly other cancers.
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Sp transcription factors are highly expressed in multiple tumors and
cancer cell lines and represent an example of non-oncogene addiction
by cancers since Sp1, Sp3 and Sp4 regulate expression of genes that
maintain the oncogenic phenotype of cancer cells without having any
mutational phenotype [1–9]. Down-regulation of Sp1, Sp3 and Sp4
factors by specific drugs or by RNA interference confirms that Sp-
regulated genes play a critical role in cancer cell growth (cyclin D1,
epidermal growth factor receptor, hepatocyte growth factor receptor),
survival (bcl-2, survivin), angiogenesis (vascular endothelial growth
factor and its receptors), and inflammation (NFκBp65) [1–9]. Most
of these genes contribute to the cancer phenotype and are themselves
individual drug targets. The high expression of Sp1, Sp3 and Sp4 in
breast and other cancer cell lines has been investigated and it was
initially reported that microRNA-27a (miR-27a)-mediated inhibition
of ZBTB10, a Sp repressor, played a role in the high expression of Sp
transcription factors [10]. A miR-27a antagomir induced ZBTB10
which resulted in down-regulation of Sp1, Sp3 and Sp4 and similar
results were observed by overexpression of ZBTB10 in breast cancer
cells or after treatment with drugs that down-regulate miR-27a [10].
Like ZBTB10, ZBTB4 is also a transcriptional repressor that
inactivates genes through binding their respective GC-rich promoters
[8,10], and ZBTB4 levels are suppressed in breast cancer cells due to
binding miR-20a, miR-17-5p and related paralogs. miR antagomirs
or ZBTB4 overexpression decreases Sp1, Sp3 and Sp4 expression in
breast cancer cells [11], which is mediated through competition to
GC-rich binding site. It was also observed that ZBTB4 but not
ZBTB10 was a significant prognostic factor in breast cancer where
high expression in patients was correlated with increased relapse free
survival of breast cancer patients [11].
Examination of publically available breast cancer patient mRNA
expression data for genes inversely correlated with ZBTB4 identified
EZH2 which is a negative prognostic factor for breast cancer patient
survival. We further investigated functional interactions between
oncogenic miR/ZBTB4 signaling axis and EZH2 and show that high
expression of EZH2 is also dependent on Sp transcription factors
which in turn are regulated by miR-20a and related paralogs through
their inactivation of ZBTB4. This report demonstrates that
overexpression of pro-oncogenic EZH2 in breast cancer is Sp-
dependent and due to disruption of miR-mediated suppression of
ZBTB4 and that EZH2 can be targeted by drugs such as betulinic
acid (BA) that down-regulate these pro-oncogenic miRs derived from
miR-106b-93 and other paralogue clusters.Materials and Methods
Cell lines, Reagents and Chemicals
MDA-MB-231 and MCF-7 cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA) and
were not further tested or authenticated by the authors. Cell lines
were maintained DMEM medium supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin solution (Sigma
Aldrich, St Louis) and maintained at 37°C in the presence of 5%
CO2. Cells (2.5 × 10
4 per well) were seeded, either transfected with
siRNAs or betulinic acid (BA), and then counted using a Coulter Z1
cell counter at the designated time points. Small interfering RNAs for
Sp1 and EZH2 were obtained from Sigma Aldrich (MISSION siRNA),
and antisense microRNA for miR-106a, miR-106b andmiR-20a were
purchased from Dharmacon (Chicago, IL).Cell Proliferation and Boyden Chamber Invasion Assay
Cells (2.5 × 104 per well) were seeded either transfected with
siRNAs or treated with betulinic acid (BA), and then counted using a
Coulter Z1 cell counter at the designated time points. For invasion
assay, a 24-well chamber of 8.0-μm pore size (Costar, Cambridge,
MA) were coated with Matrigel (BD Bioscience, San Jose, CA) and
then used for measuring tumor cell invasion after cells were
transfected with siRNAs using Lipofectamine 2000 (Invitrogen).
After 24 hr, the chamber was removed and fixed with methanol. Cell
invasion was measured by counting the attached cells to the lower
chamber surface.
Western Blotting and Quantitative Real-Time PCR
Whole cellular lysates were harvested and analyzed bywestern blots as
previously described using β-actin as a loading control [10]. Antibodies
for Sp1, Sp3 and Sp4 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). ZBTB4 and EZH2 antibodies were purchased from
Aviva Systems Biology (San Diego, CA) and Active Motif (Carlsbad,
CA), respectively. Total RNAwas extracted; cDNAswere amplified and
quantitative real-time PCR was performed as previously described [11]
and normalized to TBP. The following primers for EZH2, Sp1, Sp3,
Sp4 and TBP were purchased from Integrated DNA Technologies:
EZH2 (forward), 5′-TTC ATG CAA CAC CCA ACA CT-3′; EZH2
(reverse), 5′-GAG AGC AGC AGC AAA CTC CT-3′; Sp1 (forward),
5′-TGC AGC AGA ATT GAG TCA CC-3′; Sp1 (reverse), 5′-TTG
GTA CTG CTG CCA CTC TG-3′; Sp3 (forward), 5′-TCC AGT
CAG CAG ATG GTC AG-3′; Sp3 (reverse), 5′-TTG GGT TTG
ACCAGGAAAAG-3′. Sp4 (forward), 5′-AAACATGTCAAAACG
CAC CA-3′; Sp4 (reverse), 5′-TTG AGA AAT GGC TGC AAC TG-
3′. TBP (forward), 5′-TGC ACA GGA GCC AAG AGT GAA-3′;
TBP (reverse), 5′-CAC ATC ACA GCT CCC CAC CA-3′.
Luciferase Assay
The reporter luciferase construct containing EZH2 gene promoter
region (−1095/+48) was kindly provided by Dr. Helin (University of
Copenhagen, Copenhagen, Denmark). Transfected cells were lysed,
and luciferase activity normalized to β-galactosidase activity was
determined as described [11].
Chromatin Immunoprecipitation Assay
The chromatin immunoprecipitation (ChIP) assay was carried out
using ChiP-IT Express Magnetic Chromatin Immunoprecipitation Kit
(Active Motif, Carlsbad, CA) according to manufacturer's protocol. The
Chip primer sets used for Chip assay: Primer I (forward: −1558), 5′-
TTGCCACATGAAGCAATAGG-3′, Primer I (reverse: −1090), 5′-
CAG ACC CTT CCA CTG TTC GT-3′; Primer II (forward: −458),
5′-CTGGTTCAA ACTTGGCTTCC-3′, Primer II (reverse: −214),
5′-CTC CAC TGC CTT CTG AGT CC-3′; Primer III (forward:
+607), 5′-AGTCCGCACTCAGACAAAGG-3′, Primer III (reverse:
+1189) 5′-CAA GTT GGC CAA AAC AGC TT-3′. The positive
(GAPDH) and negative primer (CNAP1) sequences were previously
described [10,11]. Chip-PCR was performed using the 7300HT Real-
Time PCR System with a 96-well block module (Applied Biosystems)
with Primer II. Cycling conditions were 56°C for 30 min and 95°C for
10 min, followed by 50 cycles of 95°C for 25 s and 60°C for 60 s.
In Vitro Translation and Gel Shift Assay
ZBTB4 cDNA was cloned into pCDNA vector (Invitrogen,
Carlsbad, CA) vector and then in vitro translated using T7 quick
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manufacturer's protocol (Promega, Madison, WI). Sp1 recombinant
protein was purchased from Promega (Madison, WI). The DNA
binding of Sp1 and ZBTB4 to GC-rich oligos derived from EZH2
gene promoter was measured using an Universal EZ-TFA transcrip-
tion factor assay Chemiluminescent kit (Upstate Biotechnology, Inc.,
Lake Placid, NY) according to the manufacturer's protocol, and the
oligo nucleotide sequences (wild type and mutated) derived from
EZH2 gene promoter are illustrated (Supplementary Figure 3). The
biotin-conjugated GC-rich oligos and the competitive oligonucleo-
tides were purchased from Intergrated DNA Technology. The
detailed method was previously described [11].
Xenograft Study
Female athymic nude mice were purchased from the Harlan
Laboratories (Indianapolis, IN), and MDA-MB-231 cells (1×106)
mixed with matrigel (BD Biosciences, San Jose, CA) were implanted
subcutaneously into the either flank of each mouse. When the tumors
were palpable, mice were divided into two groups of 6 animals and
dosed by oral gavage with corn oil or 30 mg/kg of BA every other day
for 21 days. The mice were weighed and their tumor sizes were
measured at the indicated time with calipers. After mice were
sacrificed, the tissue lysates were collected and analyzed for measuring
protein and microRNA levels.
Tail Vein Injection Metastasis Assay
MDA-MB-231 cancer cells (106 cells) were introduced through
tail-vein injection. After 7 days, 20 mg/kg of BA or corn oil (control)
was administered to mice by oral gavage every other day for 28 days.
Mice were euthanized and lungs were analyzed for metastatic tumors.
Three mice not injected were also used as controls.
Microarray, Breast Cancer Patient Gene Profiling Data Sets,
and Statistical Analysis
MDA-MB-231 cells were transiently transfected with siRNA for
EZH2, Sp1 and control and after 48 hr, total RNA from these cells
was extracted from the indicated cell lines using a mirVana RNA
Isolation Labeling kit (Ambion, Inc.). Five hundred nanograms of
total RNA were used for amplification, labeling and hybridization
according to the manufacturer's protocols (Illumina Inc., San Diego,
CA). The data analysis was performed as previously described
[11,12]. Breast cancer patient gene expression data from four
independent breast cancer patient cohorts were used for analysis.
Normalized gene expression data from NKI, UNC and IJB cohorts
were obtained as previously described [12,13]. All gene expression
data were deposited in Gene expression Omnibus (GEO) as
GSE48979. Student's t-test (two sided) was applied to determine
statistical significance. Biometric Research Branch (BRB) ArrayTools
(National Cancer Institute, Bethesda, MD) was used for prediction of
patient survival as previously described [12,14]. Kaplan-Meier patient
survival analysis (log-rank test) was applied to predict patient survival
and DAVID (The Database for Annotation, Visualization and
Integrated Discovery) analysis was used for functional annotation of
genes [15].
Results
Identification of EZH2 as a Downstream Target of ZBTB4
ZBTB4 is a transcriptional repressor, and high expression of this
gene is a favorable prognostic factor for relapse free survival of breastcancer patients [11]: however, the identities of downstream genes
repressed by ZBTB4 have not been determined. In order to identify
novel downstream repressed genes, we first performed Pierson's
correlation analysis using two breast cancer patient genomic data sets
and identified 34 genes that were highly inversely correlated with
ZBTB4 expression (cut-off value of Pearson's correlation coefficient r
N −0.45 and P N .001) . Figure 1A shows that among 152 and 108
genes inversely correlated with ZBTB4 expression in tumors from
two different data sets of breast cancer patients [12,13] and 34 genes
are common to both groups (Suppl. Table 1). Previous studies
showed that Specificity protein1 (Sp1) mutually competes with
ZBTB4 for binding to GC-rich cis promoter element [11], and
therefore, by comparing a list of Sp1 regulated genes, determined by
Sp1 knockdown and control RNA lysates of MDA-MB-231 cells
(514 genes, N 1.5 fold change, P N .001), we identified only three
genes that were also regulated by Sp1 among 34 genes (Figure 1A).
These three genes, including EZH2, RRM2 and CDC2, would be
putative ZBTB4 downstream target genes that are likely regulated
positively by Sp1, but negatively by ZBTB4. Survival curves for
patients expressing high and low levels of ZBTB4 and EZH2 also
illustrate their inverse relationship as prognostic factors for disease-
free survival in two independent breast cancer patient data sets
[12,13](Figure 1B). The relative expression of EZH2, Sp1 and
ZBTB4 in normal breast tissue vs. breast tumor was also determined
in two additional data sets (Supplementary Figure 1) and show that
expression of ZBTB4 is inversely associated with Sp1 and EZH2 in
normal breast vs. invasive breast carcinoma.
ZBTB4-Mediated EZH2 Repression
A possible functional relationship between ZBTB4 and EZH2 was
investigated in MCF-7 and MDA-MB-231 cells by overexpression of
ZBTB4 and this resulted in down-regulation of EZH2 protein
(Figure 2A) and mRNA (Figure 2B) levels in both cell lines.
Moreover, overexpression of ZBTB4 was also accompanied by
decreased expression of Sp1, Sp3 and Sp4 protein and mRNA levels
(Figure 2A and B) and this was consistent with previous studies
showing that ZBTB4 decreased expression of Sp transcription factors
[11]. By using TRANSFAC program searching for potential
transcription factor binding sites [16], we identified two consensus
Sp1 binding sites in 5′ proximal region of EZH2 gene promoter
(Figure 2C). Luciferase activity was decreased after overexpression of
ZBTB4 in MDA-MB-231 and MCF-7 cells transfected with the
pEZH2-luc construct which contains GC-rich motifs that can bind
ZBTB4 (Figure 2C). Effects of EZH2 knockdown onMDA-MB-231
cell growth and invasion in a Boyden Chamber assay was shown
(Supplementary Figure 2) and these results were similar to the effects
of ZBTB4 overexpression in the same cell lines [11].
Sp Transcription Factors Regulate EZH2 Expression
Transfection of MDA-MB-231 with oligonucleotides targeted to
Sp1 (iSp1), Sp3 (iSp3), and Sp4 (iSp4) decreased expression of the
corresponding Sp proteins, and EZH2 expression was decreased by
iSp1 and iSp4 but not iSp3 (Figure 3A). In contrast, iSp1, iSp3 and
iSp4 all decreased EZH2 protein in MCF-7 cells demonstrating that
EZH2 was regulated by Sp transcription factors and the relative
contributions of Sp1, Sp3 and Sp4 were cell context-dependent.
Knockdown of Sp transcription factors by RNAi also decreased
luciferase activity in MDA-MB-231 and MCF-7 cells transfected
with the pEZH2-luc construct (Figure 3B) and these data correlated
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transfected with ZBTB4 expression plasmid and decreased protein expression was determined by western blots of whole cell lysates.
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(Figure 3A). Incubation of recombinant Sp1 with the GC-rich
sequence from the EZH2 promoter resulted in formation of a
retarded band and the intensity of this band was decreased upon
coincubation with 100-fold excess of a GC-rich competitor, whereasSp1 did not bind the EZH2 oligonuclectide mutated in the GC-rich
site (Figure 3C). In a parallel gel shift experiment, we showed that
binding of recombinant Sp1 to the GC-rich EZH2 promoter was
decreased when coincubated with in vitro translated recombinant
ZBTB4 protein (Supplementary Figure 4). A ChIP assay and three
1064 ZBTB4 Regulates EZH2 Expression in Breast Cancer Yang et al. Neoplasia Vol. 16, No. 12, 2014sets of primers were used to show that Sp1 was constitutively bound
to the GC-rich region of the EZH2 promoter (primer 2) but not
distant promoter region (N1 kb: primers 1 and 3) using two different
Sp1 antibodies (Figure 3C). Mithramycin is a drug that specifically
binds GC-rich promoter elements and GAL4-Sp1 DBD only
contains DNA binding domain of Sp1, and both act as dominant
negative inhibitors of Sp transcription factors [17,18]. Both
mithramycin D and GAL4 constructs containing Sp1 DBD domain
inhibit luciferase activity in MD-MB-231 and MCF-7 cells
transfected with the pEZH2-luc construct whereas overexpression
of Sp1 induced luciferase activity (Figure 3D). These data confirm
that EZH2 is regulated by Sp transcription factors and the effects of
ZBT4 overexpression on decreased expression of EZH2 (Figure 2) are
due, in part, to down-regulation of Sp1, Sp3 and Sp4.
Regulation of EZH2 Expression by Oncogenic-miR/ZBTB4
Signaling Axis
MiR-20a, miR-106a and miR-106b have common seed sequences
and are components of the miR-17-92, miR-106a-363 and miR-
106b-25 clusters respectively [19]. These miRs are overexpressed in
breast tumors [19,20] and also bind to and decrease expression of
ZBTB4 [11]. Transfection of MDA-MB-231 and MCF-7 cells with
miR-106a, miR-106b and miR-20a antagomirs decreased levels of
EZH2, Sp1, Sp3 and Sp4 proteins but increased ZBTB4 expression
(Supplementary Figure 5) in both cell lines, although the miR-106a
antagomir was not effective likely due to relatively low endogenous
expression level of miR-106a (Figure 4A and Supplementary Figure
6). Decreased luciferase activity was also observed in cells transfected
with the pEZH2-luc construct and the miR antagomirs and again
miR-106a antagomir was the least effective antagomir (Figure 4B).
The critical role of ZBTB4 in mediating the effects of the
antagomirs was further investigated in MDA-MB-231 cells using
antagomir-106b as a model. Transfection of MDA-MB-231 cells
with the antagomir alone or in combination with siZBTB4 showed
that down-regulation of EZH2, Sp1, Sp3 and Sp4 by antagomir-
106b was potentially reversed after knockdown of ZBTB4
(Figure 4C). Antagomir-106b also increased ZBTB4 and decreased
Sp1 binding to the GC-rich region of the EZH2 promoter
(Figure 4D) in a ChIP assay, confirming the important role of
miR-dependent suppression of ZBTB4 in maintaining high levels of
EZH2 (and Sp proteins) in breast cancer cells. Furthermore, the
results from Pierson's correlation analysis using NCI60 cell line miR
& mRNA array data showed positive relationship between oncogenic
miRs and EZH2 expression [21](Supplementary Figure 7).
A Clinical Significance of Sp1-Depedent EZH2 Gene
Signature in Breast Cancer
Since high expression of both Sp1 and EZH2 are observed in
invasive breast carcinoma (Figure 1C) and Sp1 regulates EZH2
expression (Figure 3), we investigated whether a common gene
signature obtained by comparing gene expression signatures after Sp1
and EZH2 knockdown in MDA-MB-231 cells possess any clinical
predictive value. The Venn diagram (Figure 5A) shows that 163 genes
(Suppl. Table 2) are commonly regulated by both Sp1 and by EZH2
knockdown. Next, gene ontology of the common 163 genes was
analyzed using DAVID [15] and the analysis shows (Figure 5B) that
major biological pathways regulated by Sp1 and EZH2 are related to
cell proliferation, cell cycle and cell death (Suppl. Table 3). In order to
test the clinical importance of the 163 gene signature, predictionmodels using multiple algorithms classifiers were employed [12], and
the patients were split into Sp1-KO (KD) or control (CT) groups
based on similarity to the gene signature in the former group. By
using NKI breast cancer patient data set [12], Relapse - free survival of
breast cancer patients in Sp1-KO and CT groups was analyzed using
7 different classifiers, including one nearest neighbor (1NN), three
nearest neighbors (3NN), nearest centroid (NC), support vector
machines (SVM), Bayesian compound predictor (BCC), compound
covariate predictor, and linear discriminator analysis. The results
(Figure 5C) show that the common gene signature after knockdown
of EZH2 or Sp1 significantly predicted relapse free patient survival by
four different classifiers, including 1NN, 3NN. NC and SVM
(Suppl. Table 4) and is consistent with the functional pro-oncogenic
activity of Sp1 and EZH2.
A Therapeutic Potential of Sp/EZH2 Oncogenic Signaling Axis
in Breast Cancer
Several anticancer drugs, including betulinic acid (BA), down-
regulate Sp1, Sp3 and Sp4 through multiple pathways [1–9]. Results
in Figure 6A show that 15 μM BA induced a time-dependent
induction of ZBTB4 and down-regulation of Sp1, Sp3, Sp4, EZH2,
miR-106a, miR-106b and miR-20a, and inhibition of MDA-MB-
231 cell proliferation (Supplementary Figure 8), demonstrating that
BA disrupted miR-ZBTB4 interactions. In vivo administration of BA
to athymic nude mice bearing MDA-MB-231 cells as xenografts
inhibited tumor growth, and H&E staining showed a more diffused
and disorganized staining pattern in tumors from corn oil (solvent)-
treated control animals compared to BA-treated animals (Figure 6B).
Lung tissue from these animals was stained with H&E to determine
lung metastasis of the breast tumors and compared to corn oil-treated
controls, and the results showed that BA inhibited colonization
potential of MDA-MB-231 cells to lung and this was quantitated
using foci in BA-treated and control lungs (Figure 6B). Moreover, BA
also decrease expression of EZH2, Sp1, Sp3 and Sp4 proteins in
tumors and this was accompanied by decreased expression of miR-
106a, miR-106b and miR20a (Figure 6C) and these data
complemented results of in vitro studies and establish that EZH2 is
regulated by Sp transcription factors which are themselves regulated
by a miR-ZBTB4 axis.
Discussion
The Polycomb Repressive Complex 2 (PRC2) exhibits histone
methyltransferase (HMT) activity that catalyzes methylation of
histone lysine residues, and PRC2-dependent gene silencing in
cancer cells and tumors results in enhanced cancer cell proliferation,
survival and metastasis [22–26]. The PRC2 complex contains three
major components: Enhancer of Zeste Homolog 2 (EZH2);
Embryonic Ectoderm Development (EED); and Suppressor Zeste
12 (SUZ12). EZH2 is the catalytic subunit of this complex and
contains domains for binding EED and SUZ12 and HMTase
activity [25,26]. EZH2 catalyzes methylation of lysine-27 of histone
H3 (H3K27), and the predominant trimethylated form (me3) is
associated with gene silencing.
EZH2 overexpression has been observed in multiple types of
cancer (reviewed in [27)], and in epidemiological studies EZH2 is
associated with highly aggressive tumors and poor patient prognosis
[28–33]. For example, in breast cancer cells transfected with siRNA
against EZH2 (siEZH2), there was decreased cell and tumor growth,
G0/G1 to S phase cell cycle arrest, and induction of apoptosis, and this
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[32–34]. Similar results were observed in other cancer cell types
with some differences with respect to siEZH2-dependent inhibition
of G0/G1 to S phase progression in breast cancer cells vs. G2/M arrest
in transformed fibroblasts [35]. EZH2 also promotes expansion of
breast tumor initiating cells, leading to enhanced β-catenin
signaling [36].
EZH2 expression is regulated by multiple transcription factors; for
example, p53 suppresses EZH2 through direct interactions with the
EZH2 promoter [37]. E2F transcription factors activate EZH2 and
bind to the EZH2 promoter and this is due to retinoblastoma protein
(Rb) and its regulation of the E2F pathway [38,39]. EZH2 is alsodirectly targeted by microRNAs-26a (miR-26a) and miR-101 and
loss of these miRs is correlated with high expression of EZH2
[39–42]. However, it is clear from this study that knockdown of Sp1,
Sp3 and Sp4 proteins by RNAi decreases EZH2 protein and mRNA
levels not only in estrogen receptor (ER)-positive MCF-7 and but also
in highly aggressive ER-negative MDA-MB-231 breast cancer cells
(Figure 3A and B). Moreover, EMSA and ChIP assays confirm that
Sp1 binds the GC-rich regions of the EZH2 promoter, and agents
such as mithramycin and a dominant negative construct (GAL4-Sp1
DBD) that inactivate transcription from GC-rich motifs also inhibit
EZH2 expression in breast cancer cells (Figure 3). BA is an anticancer
drug that decreases expression of Sp transcription factors through
siSp1
2298 genes  
> 1.25 fold
siEZH2
2357 genes  
> 1.25 fold
1632130 2189
163 genes  
commonly 
regulated 
A B
C
Fo
ld
 E
nr
ic
hm
en
t 
DAVID Analysis
Prediction analysis 
0
0.4
0.8
RFS Survival 
(months)
1NN 3NN
NC SVM
Pr
ob
ab
ili
ty
0.2
0.6
1.0
RFS Survival 
(months)
RFS Survival 
(months)
0 50 100 150 200 250 0 50 100 150 200 250
0 50 100 150 200 2500 50 100 150 200 250
RFS Survival 
(months)
0
0.4
0.8
Pr
ob
ab
ili
ty
0.2
0.6
1.0
0
0.4
0.8
Pr
ob
ab
ili
ty
0.2
0.6
1.0
0
0.4
0.8
Pr
ob
ab
ili
ty
0.2
0.6
1.0
CT
KD
CT
KD
KD KD
CTCT
P=0.005 P=0.011
P=0.045P=0.0035
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
Figure 5. The shared gene signature between Sp1 and EZH2 knockdown genes in MDA-MB-321 cells. (A) The 163 genes commonly
down-regulated (N1.25-fold). (B) Gene ontology of the 163 commonly down-regulated genes using DAVID analysis. (C) Release-free
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and in this study, BA also down-regulated Sp1, Sp3, Sp4 and EZH2
in tumors (xenografts) and MDA-MB-231 cells (Figure 6). Results of
RNAi, gel mobility shift and ChIP assays, and transfection with
antagomirs and ZBTB4 demonstrate for the first time that EZH2 is
an Sp-regulated gene in breast cancer.
ZBTB4 expression in breast cancer patients is a prognostic factor
for increased patient survival [11] (Figure 1B). EZH2 is one of 34genes whose expression is inversely correlated with ZBTB4 and, not
surprisingly, high EZH2 expression is a negative prognostic factor for
relapse- free survival of breast cancer patients (Figure 1B) [10]. Since
EZH2 is an Sp-regulated gene and ZBTB4 is an “Sp repressor” [10],
we further investigated the role of ZBTB4 as an “EZH2 repressor”
and regulation of ZBTB4-EZH2 interactions by miR-106b and other
paralogues such as miR-20a and miR-106a that are overexpressed in
breast cancer patients [19,20] and target (repress) ZBTB4 [10]. Of
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inversely correlated with ZBTB4 expression, suggesting that they
possible mutual regulation of expression, which is consistent with
results illustrated in Figures 2A, 6A and Supplementary Figure 9.
Members of the miR-17-92, miR-106a-363 and miR-106b-25
clusters such as miR-20a, miR-106a and miR-106b have identical
seed sequence, and previous studies in this laboratory show that
ZBTB4 is suppressed by these miRs in breast cancer cells [10]. Since
miR-dependent suppression of ZBTB4 facilitates high expression of
Sp1, Sp3 and Sp4, it is not surprising that both overexpression ofZBTB4 or miR-20a, miR-106a andmiR-106b antagomirs all decrease
expression of EZH2 in breast cancer cells (Figures 4 and 5) and this
suppression is associated with recruitment of ZBTB4 and loss of Sp1
on the EZH2 promoter (Figure 4D). Our results also show that
knockdown of Sp1 and Sp4 (or overexpression of ZBTB4) decreases
miR-20a, miR-106a and miR-106b levels in MDA-MB-231 cells
(Figure 5C). Betulinic acid also decreases EZH2, Sp1, Sp3 and Sp4
expression in breast cancer cells and this is consistent with the decrease
of Sp transcription factors by betulinic acid in other cancer cell lines
[1,2,5,43–45]. Betulinic acid-induced disruption of the miR-ZBTB4
1068 ZBTB4 Regulates EZH2 Expression in Breast Cancer Yang et al. Neoplasia Vol. 16, No. 12, 2014interactions (Figure 6A and C) suggest that mechanism of action
primarily involves transcriptional repression (Figure 6D). The inverse
relationship between ZBTB4 and EZH2 in terms of prognosis for
disease-free survival and expression patterns (Figures 1C and 4D) also
correlates with their different functional activities in breast cancer
[11,30–36]. Since Sp1 regulates EZH2 expression, we also examined
the prognostic significance and association of Sp1 and EZH2 in gene
profiling studies and show by RNAi that Sp1 and EZH2 regulate
expression of 163 genes in common which in turn are primarily
involved in cell proliferation and cell death pathways (Figure 5B and
Supplementary Table 3). Moreover, the prognostic importance of the
shared Sp1/EZH2-dependent 163 gene expression signature using
seven different algorithm prediction analyses [12] show that this
common gene signature is significantly associated with relapse-free
survival of breast cancer patients when assessed at least by four
different classifiers (Figure 5C). This is consistent with our functional
studies showing that Sp transcription factors potentially represent an
important class of non-oncogenes that are essential for maintaining the
breast tumor phenotype without exhibiting anymutational phenotype
[46-48].
In summary, our results demonstrate that expression of EZH2 in
breast cancer is regulated by both Sp transcription factors (expression)
and ZBTB4 (repression) (Figures 2 and 3). The breast cancer
phenotype which features high expression of Sp1, Sp3, Sp4, EZH2
and other Sp-regulated genes is maintained by miR-dependent
suppression of ZBTB4, and drugs such as BA that target miR
downregulation inhibit tumor growth, in part, through increasing
ZBTB4/Sp ratios. Previous studies show that miR-27a-dependent
suppression of the Sp repressor ZBTB10 also contributes to high
expression of Sp transcription factors in breast cancer [10,44,45], and
miR-27a:ZBTB10 interactions would also contribute to the pathways
illustrated in Figure 6D. However, in contrast to ZBTB4, ZBTB10
expression is not a significant prognostic factor and is not inversely
correlated with EZH2 expression in breast tumors, suggesting that
ZBTB4 may regulates a distinct set of genes compared to ZBTB10.
Moreover, using both EZH2 and ZBTB4 expression as
double prognostic markers shows the combined marker
(EZH2highZBTB4low vs. EZH2lowZBTB4high groups) was more
effective as a prognostic indicator than either ZBTB4 or EZH2 alone
(Supplementary Figure 10). Our future studies are focused not only
on miR-ZBTB (repressor)-dependent regulation of EZH2 but also on
the function of the PRC2 complex and PRC2-regulated genes. We
are also developing drugs such as betulinic acid that target the PRC2
complex in cancer cells and tumors, since this would be a novel
therapeutic approach for combination therapies with radiation and
other chemotherapeutic agents.Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.09.011.
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